Our second Perspectives video features PSEC member Dr. Patrick Nana-Sinkam’s interview with 2022 ASCI inductee Valerie A. Arboleda, MD, PhD (view profile), Assistant Professor of Pathology, Laboratory Medicine, and Human Genetics at the University of California, Los Angeles. Dr. Arboleda’s research focuses on the application of next-generation sequencing to understand the basis of genetic syndromes. She talks about her scientific background; her contribution to developing an FDA-approved scalable COVID-19 test; and the need to improve equity in genetic testing.
John Hawley
From the JCI Editor: New Impact Factor and launch of Research Letters
On behalf of the Journal of Clinical Investigation’s Editorial Board, I am humbled by the opportunity to serve the ASCI and to have the privilege of determining the cutting-edge biomedical research published by the Journal. I am delighted to share with you that the JCI’s latest Journal Impact Factor (IF) is 19.456, representing a 24% increase from the previous year. Our sister journal, JCI Insight, has also increased its IF, which now stands at 9.484. This strong performance highlights the strength of our authors’ articles and reflects the importance of our mission to understand the basis of human disease. We are grateful to our authors for entrusting us with their work, to our reviewers and consulting editors for their dedication to maintaining the highest standards, and to the prior editorial team at Johns Hopkins for their expert leadership during the unprecedented challenges of the pandemic. These successes affirm the ASCI’s voice and the critical role of societies in the publishing landscape.
As stewards of the JCI, the Northwestern-based Editorial Board is dedicated to continuing and improving the Journal’s record of excellence. We encourage submission of Research manuscripts that define disease processes. We welcome work that utilizes human data, from “n of one” to “big data” studies, while remaining interested in translationally relevant animal models and preclinical investigation. We also encourage Clinical Medicine submissions focused on human studies that have the potential to impact clinical practice or inform understanding of diseases.
Recognizing the need to disseminate certain high-impact findings quickly, we have launched a new submission category, Research Letters — focused reports of an original preclinical or clinical research finding of exceptional interest to the JCI readership presented in a single-figure (or -table) format.
As a reminder, ASCI dues-paying members who are the corresponding author of a first-round submission to the JCI, and whose dues are current, may designate one submission per calendar year to be guaranteed for external peer review. We encourage you to take advantage of this benefit by sending us your best work that advances the understanding of pathogenesis.
I wish you all the best and thank you for your support of the JCI.
Sincerely,
Elizabeth M. McNally, MD, PhD
Editor, The Journal of Clinical Investigation
Officer, ASCI Council
Consuelo H. Wilkins, MD, MSCI – full video (July 2022)
The PSEC is proud to initiate the ASCI Perspectives series with DEIC member Dr. Patrick Nana-Sinkam’s (elected 2019; view profile) interview with Consuelo H. Wilkins, MD, MSCI (elected 2022; view profile). Dr. Wilkins is Chief Equity Officer and Senior Associate Dean for Health Equity and Inclusive Excellence; Associate Director of the Vanderbilt Institute for Translational Science; and Professor of Medicine, Division of Geriatric Medicine, Vanderbilt University. She was elected to the National Academy of Medicine in 2020. In the interview, Dr. Wilkins, a leading health equity researcher, discusses the origins of her research path and shares lessons learned.
Recipient of the 2022 Seldin~Smith Award for Pioneering Research: Piro Lito, MD, PhD
The American Society for Clinical Investigation (ASCI) is pleased to recognize Piro Lito, MD, PhD, as the recipient of the 2022 Donald Seldin~Holly Smith Award for Pioneering Research. Dr. Lito receives an honorarium of $30,000 to advance his academic efforts and will deliver a scientific talk at the 2023 AAP/ASCI/APSA Joint Meeting.
Dr. Lito has worked to understand KRAS oncoprotein signaling in cancer. Approximately 25% of patients with lung cancer have KRAS mutations; and ~13% of these have the specific mutation G12C. Dr. Lito demonstrated that KRAS mutants are not locked in their active state but rather cycle between their active and inactive states in cancer cells. Further, he described the mechanism by which KRAS G12C can be inhibited by drugs that target its inactive state, rendering it unable to contribute to further tumor growth. In addition, Dr. Lito co-led the first-in-human clinical trial of the KRAS G12C inhibitor sotorasib, work that paved the way for the US FDA’s approval of sotorasib in 2021.
Frank McCormick, PhD, FRS, DSc (Hon), who is Professor, UCSF Helen Diller Family Comprehensive Cancer Center, supported Dr. Lito’s nomination, noting that “Piro is exemplary of the kind of person we should support with the Seldin~Smith Award. He has tremendous potential to conduct high‐risk and potentially groundbreaking research.”
Dr. Lito earned his BS, PhD, and MD from Michigan State University. He subsequently completed his internship and residency in internal medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School. He did his clinical fellowship in medical oncology and postdoctoral research at the Memorial Sloan Kettering Cancer Center, where he is currently Associate Member and Attending Physician. Dr. Lito’s research has been supported in part by the National Cancer Institute. He is a Pew-Stewart Scholar in Cancer Research, a Damon Runyon Clinical Investigator, a recipient of the 2018 ASCI’s Young Physician-Scientist Awards, and the recipient of the 2021 Trailblazer Prize for Clinician Scientists by the Foundation of the National Institutes of Health. He was elected to the ASCI in 2021.
Nominations were evaluated by the Seldin~Smith Award Selection Committee: Mukesh K. Jain (Chair), Vivian G. Cheung, Charles L. Sawyers, Elizabeth M. McNally, W. Kimryn Rathmell, and Lorraine Ware. Finalists were evaluated by an Advisory Committee comprising five physician-scientist luminaries: Joseph L. Goldstein (Chair), Michael S. Brown, Robert J. Lefkowitz, Christine Seidman, and Arthur Weiss.
Message from Sohail Tavazoie, the incoming 2022-2023 President
I am incredibly honored to start my term as ASCI President. My four years on Council revealed to me the critical roles our members and organization play in benefiting society. The scientific study of human disease improves human health, enhances our fundamental understanding of biology, supports our economy, spawns new and previously unforeseeable disciplines, and is the most privileged profession imaginable for many of us.
It is my hope that we will better support and enable current and future physician-scientists to have the opportunities we’ve had so they can make the transformative discoveries of tomorrow. To this end, we wish to hear from you. We will be sending members a survey to inform our Council about the needs, challenges, and aspirations of our members and their physician-scientist trainees. I have also begun an initiative to highlight and promote the scientific and personal histories of our membership. To do this, we will be requesting your research interests, recent key publications, and a short video, all of which will be posted on an updated ASCI website and directory. This will serve to inspire physician-scientist trainees, enhance their recruitment into members’ labs, and foster interactions, collaborations, and support networks in our community.
We will also soon announce the details of two awards aimed at recognizing outstanding mid-career members, and we are planning additional initiatives to nurture the careers of physician-scientist trainees and junior faculty members.
You can follow these developments on Twitter @the_asci, @AsciPresident, the JCI @jclinicalinvest, and JCI Insight @jci_insight.
Sincerely,
Sohail Tavazoie, MD, PhD
Message from Hossein Ardehali, the outgoing 2021-2022 President
I have completed my 2021-2022 Presidential term and am grateful for the trust the membership placed in me by electing me to serve in this special capacity. It has been a true and humbling honor for me, having immigrated as a teenager from war-torn Iran to the US, where I was able to pursue the physician-scientist career path. In my Presidential Address at April’s Joint Meeting, I talked about my personal history as an immigrant but more importantly the significance of immigration to science and technology in the US, which I hope will continue to be a symbol of freedom and remain open to the world. (Watch the video.)
I’m pleased that we were able to accomplish the following initiatives during my term:
- We created the ASCI Scientific Sessions, monthly presentations from accomplished investigators, free and open to all, through the academic year. We started in September 2021 with Dr. Bill Kaelin and finished this cycle with Dr. Charles Sawyers. (See the 2021-2022 archive.) The 2022-2023 ASCI Scientific Sessions will start in September 2022.
- We increased programming for early-career physician-scientists, including the ASCI’s Physician-Scientist Pathway Series, a periodic informal discussion between a senior ASCI member and the ASCI’s early-career awardees (more below). Thank you to Drs. Miriam Merad and Sangeeta Bhatia for their participation as we started this Series.
- We strengthened international outreach, notably to the Association of Physicians of Great Britain and Ireland, with ongoing discussion regarding tangible collaborations between our respective groups.
- We started a quarterly summary of ASCI activities and information (this email being a continuation of that initiative).
I give my thanks to Drs. Lorraine Ware, Kim Rathmell, and Kieren Marr, who preceded me when I started on the Presidential path and who provided great examples of leadership, and to the many Council members with whom I’ve served since being elected to the Council in 2016. All have contributed significant time and effort to ensure the ASCI’s success. I also want to thank my friend and colleague, John Hawley, and the rest of the ASCI staff for their continuous support and for their hard work in the past year. Dr. Sohail Tavazoie succeeds me as 2022-2023 President. Join me in wishing him the best for his term.
Sincerely,
Hossein Ardehali, MD, PhD @ArdehaliHossein
The 2022 Harrington Prize for Innovation in Medicine: James E. Crowe, Jr., MD, and Michel C. Nussenzweig, MD, PhD
The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and Professor, Departments of Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, and Michel C. Nussenzweig, MD, PhD, Investigator, HHMI, and Zanvil A. Cohn and Ralph M. Steinman Professor, The Rockefeller University. The award recognizes their groundbreaking work, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.
The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.
Dr. Crowe has advanced the discovery of human monoclonal antibodies for many of the most pathogenic viruses that cause human disease. His team has discovered thousands of human monoclonal antibodies for SARS-CoV-2 (the virus that causes COVID-19) and facilitated their development, transferring clinical leads to multiple pharmaceutical partners including tixagevimab + cilgavimab, now in use in high risk patients. His work on the genetic and structural basis of virus neutralization has also revealed important principles that are being exploited in new vaccine and antibody development.
Dr. Nussenzweig addressed a critical issue in immunology – the lack of a detailed understanding of the human antibody response – by developing robust and scalable methods for cloning antibodies from single human B cells. Dr. Nussenzweig showed that antibodies cloned directly from humans can be a safe and effective treatment against viral infections when passively transferred to other humans. His work established a paradigm that made it possible for him and others to rapidly develop monoclonal antibody therapies against SARS-CoV-2.
A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from eight countries before selecting the 2022 Harrington Prize recipients.
“Drs. Crowe and Nussenzweig are extraordinary physician-scientists who took distinct and separate paths but arrived at the same endpoint. In doing so, they have taught us a great deal about the human immune response and have successfully translated those findings into therapies for patients. The creativity, innovation and clinical impact demonstrated by their work is precisely what The Harrington Prize seeks to recognize,” said Hossein Ardehali, MD, PhD, Professor of Medicine in the Division of Cardiology at Northwestern Medicine and the 2021-2022 President of the ASCI.
“The translational implications of Dr. Crowe’s and Dr. Nussenzweig’s work are quite profound. Their antibody-based therapies have enabled the medical community to more effectively combat COVID, and will spare untold human suffering,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.
In addition to sharing the Prize’s $20,000 honorarium, co-recipients Dr. Crowe and Dr. Nussenzweig will deliver The Harrington Prize Lecture at the 2022 AAP/ASCI/APSA Joint Meeting on April 8, will be featured speakers at the 2022 Harrington Scientific Symposium May 25-26, and will co-publish an essay in the Journal of Clinical Investigation.
Since its establishment, The Harrington Prize has recognized outstanding and diverse innovation in medicine:
- 2014: Harry Dietz, MD, Johns Hopkins University, for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults.
- 2015: Douglas R. Lowy, MD, The National Cancer Institute, in recognition of his discoveries that led to the development of the Human Papillomavirus vaccine to prevent cervical cancer.
- 2016: Jeffrey M. Friedman, MD, PhD, The Rockefeller University, for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders.
- 2017: Jointly awarded to Daniel J. Drucker, MD, Mount Sinai Hospital, Canada, Joel F. Habener, MD, Massachusetts General Hospital, and Jens J. Holst, MD, DMSc, University of Copenhagen, Denmark, for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.
- 2018: Helen H. Hobbs, MD, UT Southwestern Medical Center, for the discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, which has improved the treatment of high cholesterol.
- 2019: Carl H. June, MD, University of Pennsylvania, for advancing the clinical application of CAR T therapy for cancer treatment, and for his sustained contributions to the field of cellular immunology.
- 2020: Stuart H. Orkin, MD, Harvard University, for breakthrough discoveries on red blood cells that offer new treatments for patients with sickle cell disease and beta-thalassemia, which are among the most common genetic disorders.
- 2021: Warren J. Leonard, MD, and John J. O’Shea, MD, NIH, for their respective contributions to the field of immunology, from fundamental discovery to therapeutic impact.
Recognizing donors to the ASCI’s 2021–2022 annual appeal
Since November, as part of our 2021–2022 annual appeal, we have been raising funds to advance ASCI programs serving early-career physician-scientists.
The appeal is officially complete – thank you for making it a success! Kim Rathmell, John Hawley, and The Sawyers Family Fund issued challenges and you, our members, met and exceeded them, raising $53,825 from 122 members, many of you giving for the first time.
The ASCI’s program initiatives are designed to help reduce attrition on the physician-scientist career path by providing our early-career colleagues with resources and networking uniquely available through our community. By fostering connections across all physician-scientist career stages and disciplines, we are able to amplify the impact of our programs on early-career physician-scientists.
As Councilor Anna Greka wrote as part of this appeal:
“Our ASCI colleagues have served as our trusted guides on the physician-scientist career path. I am certain many of you feel the same way. I am convinced that the “tap on the shoulder” that I received as a 2014 Young Physician-Scientist Awardee was critically important at a pivotal time in my career.”
We agree that the ASCI community itself plays a critical role in supporting those just starting on the physician-scientist career path. We are encouraged by what we have been able to accomplish with your support thus far and are excited about the year ahead.
Thank you to the donors listed below for their generosity in supporting the next generation of physician-scientists and for believing in the promise of our early-career colleagues.
Sincerely,
Hossein Ardehali, MD, PhD
2021-2022 President
The American Society for Clinical Investigation
With gratitude to:
Kjersti M. Aagaard, MD, PhD
David H. Alpers, MD
Frank A. Anania, MD
Mark S. Anderson, MD, PhD
Andrew Arnold, MD
Valder R. Arruda, MD, PhD
Maryam M. Asgari, MD, MPH
Jeffrey R. Balser, MD, PhD
Jonathan Barasch, MD, PhD
Rebecca Marlene Baron, MD
Julie Anne Bastarache, MD
Robert D. Beauchamp, MD
Edward John Benz, Jr.
Timothy R. Billiar, MD
Matthew D. Breyer, MD
Myles A. Brown, MD
Nancy J. Brown, MD
Martin D. Burke, MD, PhD
Manish J. Butte, MD, PhD
Kathleen R. Cho and Eric Fearon
Sung-Won Won Choi, MD, MS
Robert J. Coffey Jr., MD
Philip L. Cohen, MD
Barry S. Coller, MD
Kathleen L. Collins, MD, PhD
Max D. Cooper, MD
William G. Couser, MD
Andrea Lynn Cox, MD, PhD
James A. DeCaprio, MD
Abhinav Diwan, MBBS
Norman H. Edelman, MD
Oliver Eickelberg, MD
Stephanie Eisenbarth in honor of George Eisenbarth
James A. Fagin, MD
Garret A. FitzGerald, MD
Irving H. Fox, MD
Sherita Hill Golden, MD, MHS
Celso E. Gomez-Sanchez, MD
William B. Greenough III, MD
Anna Greka, MD, PhD
Johann E. Gudjonsson, MD, PhD
Karen Guth
Tina V. Hartert, MD, MPH
John B. Hawley
Anna Ryan Hemnes, MD
Sarah Henrickson
Helen H. Hobbs, MD
Tobias M. Hohl, MD, PhD
Thomas H. Hostetter, MD
Priscilla Hsue, MD
Thomas J. Hudson, MD
Benjamin D. Humphreys, MD, PhD
Peter Igarashi, MD
Shuta Ishibe, MD
Rajan and Angela Jain
Peng Ji, MD, PhD
Dan S. Kaufman, MD, PhD
Daniel P. Kelly, MD
Philip A. Kern, MD
Thomas R. Kleyman, MD
Heidi H. Kong, MD, MHSc
Shyamasundaran Kottilil, MD, PhD
Hrishikesh S. Kulkarni
Dr. Brendan and Maria Lee
Janet Lee and Matthew Rosengart
Erica and Ross Levine
MacRae Fort Linton, MD
Shelly C. Lu, MD
Mark A. Magnuson, MD
Douglas L Mann, MD
Denise Marciano
Kenneth B. Margulies, MD
Robert Mason, MD
Colleen McGarry
Samia Mora, MD, MHS
Nima Mosammaparast, MD, PhD
Louis J. Muglia, MD, PhD
Ann Mullally, MD
Peter Mundel, MD
Nicolas Musi, MD
The Narla family
Paul Nghiem in honor of William Bremner
Paul Wesley Noble, MD
Sophie Paczesny, MD, PhD
John Erik Pandolfino, MD, MSCI
Thalia Papayannopoulou in memory of Dr. George Stamatoyannopoulos
Ben Ho Park
John D. Parker, MD, FRCP(C)
Michael S. Parmacek, MD
Jane R. Parnes, MD
Aimee S. Payne, MD, PhD
Mark R. Philips, MD
Barry I. Posner, MD, FRS(C)
W. Kimryn Rathmell, MD, PhD
Kyu Y. Rhee, MD, PhD
Jerome Ritz, MD
Eileen Rojas
Paul B. Rothman, MD
Sanjay Saint, MD, MPH
The Sawyers Family Fund
Victor Schuster, MD in memory of Donald Seldin, MD
Drs. Lawrence Schwartz and Anne-Marie Irani
Christine Edry Seidman, MD
Kevin Navin Sheth, MD
Ben Z. Stanger, MD, PhD
Clifford J. Steer, MD
David A. Stoltz, MD, PhD
Natalie J. Torok, MD
Simeon Taylor, MD, PhD
Jennifer Lynn Taylor-Cousar, MD, MSCS
Robert F. Todd, III, in honor of Tachi Yamada, a mentor and friend
Peter Tontonoz, MD, PhD
Deborah J. Veis, MD, PhD
Liewei Wang, MD, PhD
Lorraine B. Ware, MD
Xander H.T. Wehrens, MD, PhD
Mary A. Whooley, MD
Christopher S. Williams, MD, PhD
Jedd D. Wolchok, MD, PhD
Alan S. L. Yu, MB, BChir
John L. Ziegler, MD, MSc
Guy A. Zimmerman, MD
Every attempt has been made to accurately recognize donors. Please send any updates or corrections to staff@the-asci.org.
The 2022 Stanley J. Korsmeyer Award: Peter Tontonoz, MD, PhD
Peter Tontonoz, MD, PhD, is the recipient of the 2022 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation (ASCI) for his contributions to the understanding of the regulatory pathways of lipid metabolism and their effect on normal physiology and metabolic disease.
Dr. Tontonoz received a bachelor’s degree from Wesleyan University and did graduate research under the mentorship of Bruce Spiegelman, PhD, at the Dana-Farber Cancer Institute. He received his MD and doctoral degrees from Harvard Medical School, completed his residency in Clinical Pathology at the University of California, San Diego, Medical Center, and a postdoctoral fellowship with Ronald Evans, PhD, at the Salk Institute.
Obesity, diabetes, and cardiovascular disease together constitute a significant morbidity and mortality burden worldwide; dysregulation of lipid metabolism is the connection between these diseases. Dr. Tontonoz’s laboratory focuses on the regulatory pathways that govern cholesterol, fatty acid, and phospholipid metabolism, and has helped to discover fundamental mechanisms by which animals maintain cellular and whole-body lipid homeostasis.
His research has revealed that the lipid-activated nuclear receptors LXR (liver X receptor) and PPAR (peroxisome proliferator-activated receptor) coordinate lipid metabolism and modulate immunity and inflammation, and his laboratory has demonstrated that the LXR and PPAR signaling pathways play important roles in atherosclerosis, insulin resistance, and immune responses.
His laboratory continues work to identify downstream mechanisms by which LXR, PPARs, and their target genes regulate lipid and immune homeostasis. This has resulted in the identification and characterization of IDOL, the lncRNAs LeXis and MeXis, the phospholipid remodeling enzyme Lpcat3, and, most recently, the Aster family of proteins. Notably, his research has shown that this family of proteins controls how cholesterol moves from the plasma membrane to the endoplasmic reticulum and that these proteins are broadly important for cholesterol use in steroidogenic and metabolic tissues.
Dr. Tontonoz is the Frances and Albert Piansky Endowed Chair and Distinguished Professor of Pathology and Laboratory Medicine and of Biological Chemistry at the University of California, Los Angeles (UCLA). He is Co-Director of the UCSD/UCLA Diabetes Research Center and Vice Chair for Research in UCLA’s Department of Pathology and Laboratory Medicine. His work has been supported by the US National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, the American Heart Association, and the Leducq Foundation, and he was a Howard Hughes Medical Institute Investigator from 2000 to 2017. He has mentored over 40 medical and scientific trainees who have gone on to successful careers in academia, industry, and elsewhere.
For his contributions, Dr. Tontonoz has received the Richard E. Weitzman Memorial Award of the Endocrine Society (2005), the Jeffrey M. Hoeg Award for Atherosclerosis Research of the American Heart Association (2010), the Gerald D. Aurbach Award of the Endocrine Society (2014). He was elected to the Association of American Physicians in 2014, the National Academy of Sciences in 2020, and the National Academy of Medicine in 2021. Elected to the ASCI in 2004, Dr. Tontonoz was subsequently elected to serve on the ASCI Council as Councilor, 2008-2011, and as a Council Officer, starting in 2011 and culminating in service as ASCI President from 2013 to 2014.
New members elected for 2022
The ASCI is pleased to announce the election of 95 new members for 2022.
These new members come from 46 different institutions and represent excellence across the breadth of academic medicine. They will be officially inducted into the Society at the ASCI Dinner and New Member Induction Ceremony, April 8, 2022, as part of the AAP/ASCI/APSA Joint Meeting, April 8-10, at the Swissotel Chicago.
For the 2022 membership nomination cycle, the Council considered 227 nominations and recommended 95 nominees for election. The Active and Senior segments of the membership voted on the recommendation, with 45% of eligible voters submitting their ballots by the deadline. The vote was overwhelmingly in favor of approving the recommendation.
Dr. Priscilla Hsue, the 2021-2023 Secretary-Treasurer, oversaw and served as one of the three required auditors of the ballot. Drs. Sohail F. Tavazoie and Benjamin D. Humphreys volunteered to serve as the other two auditors who reviewed and confirmed the results.
| Nominee | Institution |
|---|---|
| Opeolu Makanju Adeoye, MD, MS, FACEP, FAHA | Washington University School of Medicine in St. Louis |
| Suneet Agarwal, MD, PhD | Harvard Medical School, Boston Children’s Hospital |
| Andrew James Aguirre, MD, PhD | Harvard Medical School, Dana-Farber Cancer Institute |
| Emmanuel S. Antonarakis, MD | University of Minnesota Medical School |
| Andrea Borghese Apolo, MD | NIH, National Cancer Institute (NCI) |
| Valerie A. Arboleda, MD, PhD | University of California, Los Angeles, David Geffen School of Medicine |
| Tarek M. Ashkar (El-Achkar), MD | Indiana University School of Medicine |
| Justin R. Bailey, MD, PhD | Johns Hopkins University School of Medicine |
| Ashwin Balagopal, MD | Johns Hopkins University School of Medicine |
| Nisha Bansal, MD, MAS | University of Washington School of Medicine |
| Grant D. Barish, MD | Northwestern University Feinberg School of Medicine |
| Vivek Bhalla, MD | Stanford University School of Medicine |
| Florence T. Bourgeois, MD, MPH | Harvard Medical School, Boston Children’s Hospital |
| Rebecca J. Brown, MD, MHSc | NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Ann Chahroudi, MD, PhD | Emory University School of Medicine |
| William Checkley, MD, PhD | Johns Hopkins University School of Medicine |
| Grace Yi Chen, AB, MD, PhD | University of Michigan Medical School |
| Ying Maggie Chen, MD, PhD | Washington University School of Medicine in St. Louis |
| Daniel S. Chertow, MD, MPH | National Institutes of Health |
| Julio A. Chirinos, MD, PhD | University of Pennsylvania Perelman School of Medicine |
| Vineet Chopra, MBBS, MD, MSc | University of Michigan Medical School |
| Toni K. Choueiri, MD, MS | Harvard Medical School, Dana-Farber Cancer Institute |
| Charles S. Dela Cruz, MD, PhD | Yale School of Medicine |
| Shadmehr (Shawn) Demehri, MD, PhD | Harvard Medical School, Massachusetts General Hospital |
| Michelle R. Denburg, MD, MSCE | Children’s Hospital of Philadelphia |
| Hitesh S. Deshmukh, MD, PhD | Cincinnati Children’s Hospital |
| Michael W. Donnino, MD | Harvard Medical School, Beth Israel Deaconess Medical Center |
| Stavros George Drakos, MD, PhD | University of Utah School of Medicine |
| Areej El-Jawahri, MD | Harvard Medical School, Massachusetts General Hospital |
| Scott E. Evans, MD, FCCP, ATSF | University of Texas MD Anderson Cancer Center |
| Zachary Freyberg, MD, PhD | University of Pittsburgh School of Medicine |
| Ankush Gosain, MD, PhD | University of Tennessee Health Science Center |
| Rebecca F. Gottesman, MD, PhD | NIH, National Institute of Neurological Disorders and Stroke (NINDS) |
| Maria Monica Gramatges, MD, PhD | Baylor College of Medicine |
| Pamela Ann Guerrerio, MD, PhD | NIH, National Institute of Allergy and Infectious Diseases (NIAID) |
| Natasha B. Halasa, MD, MPH | Vanderbilt University School of Medicine |
| Neil A. Hanchard, MBBS (Hons), DPhil | NIH, National Human Genome Research Institute (NHGRI) |
| Ronna P. Hertzano, MD, PhD | University of Maryland School of Medicine |
| Andrew C. Hsieh, MD | Fred Hutchinson Cancer Research Center |
| Peter William Hunt, MD | University of California, San Francisco, School of Medicine |
| Rajan Jain, MD | University of Pennsylvania Perelman School of Medicine |
| Manuel E. Jimenez, MD | Rutgers, Robert Wood Johnson Medical School |
| Audrey R. Odom John, MD, PhD | Children’s Hospital of Philadelphia |
| Lori Chaffin Jordan, MD, PhD | Vanderbilt University School of Medicine |
| Kristopher Thomas Kahle, M.D., Ph.D. | Harvard Medical School, Massachusetts General Hospital |
| Rosandra N. Reich Kaplan, MD | NIH, National Cancer Institute (NCI) |
| Navin Kumar Kapur, MD | Tufts Medical Center |
| Matthew S. Kayser, MD, PhD | University of Pennsylvania Perelman School of Medicine |
| Brian Sangwoo Kim, MD, MTR | Washington University School of Medicine in St. Louis |
| Katherine Yudeh King, MD, PhD | Baylor College of Medicine |
| Jason S. Knight, MD, PhD | University of Michigan Medical School |
| Tim Lahm, MD, ATSF | National Jewish Health |
| Kory J. Lavine, MD, PhD | Washington University School of Medicine in St. Louis |
| Nicholas J. Leeper, MD | Stanford University School of Medicine |
| Jonathan Zheng Li, MD, MMSc | Harvard Medical School, Brigham & Women’s Hospital |
| Joseph C. Liao, MD | Stanford University School of Medicine |
| Kathleen Dori Liu, MD, PhD, MAS | University of California, San Francisco, School of Medicine |
| Thomas E. Lloyd, MD, PhD | Johns Hopkins University School of Medicine |
| Jayme Elizabeth Locke, MD, MPH | University of Alabama at Birmingham School of Medicine |
| Randy Scott Longman, MD, PhD | Weill Cornell Medical College |
| Scott A. Lorch, MD, MSCE | University of Pennsylvania Perelman School of Medicine |
| Jennifer W. Mack, MD, MPH | Harvard Medical School, Dana-Farber Cancer Institute |
| Vincent Charles Marconi, MD | Emory University School of Medicine |
| Gregory Maurice Marcus, MD | University of California, San Francisco, School of Medicine |
| Emanual Maverakis, MD | University of California, Davis, School of Medicine |
| Florencia McAllister, MD | University of Texas MD Anderson Cancer Center |
| Saurabh Mehandru, MD, MBBS | Icahn School of Medicine at Mount Sinai |
| Raina M. Merchant, MD, MSHP | University of Pennsylvania Perelman School of Medicine |
| Luc G.T. Morris, MD, MSc, FACS | Memorial Sloan Kettering Cancer Center |
| Susanna Naggie, MD, MHS | Duke University School of Medicine |
| Ken Nakamura, MD, PhD | Gladstone Institutes |
| Pradeep Natarajan, MD, MMSc | Harvard Medical School, Massachusetts General Hospital |
| Lise E. Nigrovic, MD, MPH | Harvard Medical School, Boston Children’s Hospital |
| Marcella Nunez-Smith, MD, MHS | Yale School of Medicine |
| Sara Isabel Pai, MD, PhD, FACS | Harvard Medical School, Massachusetts General Hospital |
| Sudarshan Rajagopal, MD, PhD | Duke University School of Medicine |
| Matthew T. Rondina, MD, MS | University of Utah School of Medicine |
| Mohammad Mohseni Sajadi, MD | University of Maryland School of Medicine |
| Tamer I. Sallam, MD, PhD | University of California, Los Angeles, David Geffen School of Medicine |
| Mara Ann Schonberg, MD, MPH | Harvard Medical School, Beth Israel Deaconess Medical Center |
| Robert Edward Schwartz, MD, PhD | Weill Cornell Medical College |
| Julie Kristina Schwarz, MD, PhD | Washington University School of Medicine in St. Louis |
| Anthony Kinmen Shum, MD | University of California, San Francisco, School of Medicine |
| Mark J. Siedner, MD, MPH | Harvard Medical School, Massachusetts General Hospital |
| Markus David Siegelin, MD | Columbia University College of Physicians & Surgeons |
| Jason L. Sperry, MD, MPH | University of Pittsburgh School of Medicine |
| Anish Thomas, MBBS, MD | NIH, National Cancer Institute (NCI) |
| Anne-Catrin Uhlemann, MD, PhD | Columbia University College of Physicians & Surgeons |
| Nikhil Wagle, MD | Harvard Medical School, Dana-Farber Cancer Institute |
| David Nathan Wald, MD, PhD | Case Western Reserve University School of Medicine |
| Emily Wang, MD, MAS | Yale School of Medicine |
| Michael Emmerson Ward, MD, PhD | NIH, National Institute of Neurological Disorders and Stroke (NINDS) |
| Consuelo H. Wilkins, MD, MSCI | Vanderbilt University School of Medicine |
| Rachel Lynne Zemans, MD, MA | University of Michigan Medical School |
| Shan Zha, MD, PhD | Columbia University College of Physicians & Surgeons |